<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03682393</url>
  </required_header>
  <id_info>
    <org_study_id>KUH5101126</org_study_id>
    <nct_id>NCT03682393</nct_id>
  </id_info>
  <brief_title>Post-operative Corticosteroid Treatment After Mitral Valve Surgery</brief_title>
  <acronym>MitralPOCS</acronym>
  <official_title>Does Post-operative Corticosteroid Treatment Prevent New-onset Atrial Fibrillation After Mitral Valve Surgery?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kuopio University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kuopio University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to intestigate whether three days intravenous corticosteroid
      management prevent atrial fibrillations in adults after mitral valve surgery. Prospective
      double-blinded randmized international multicenter study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Voluntary adult patients, who do not have persistent atrial fibrillation before mitral valve
      sugery will receive either intravenous corticosteroid or placebo on three postoperative days
      after mitral valve surgery. End points are atrial fibrillation onset or fullfilling the three
      days time limit. The study is double-blinded, randomized, prospective study and the aim is to
      recruite 240 patients. Patients are recruited from Oulu University Hospital, Finland, Kuopio
      University Hospital, Finland, Helsinki University Hospital, Finland, Turku University
      Hospital, Finland, Tampere Univerisity Hospital, Finland, Tartu University Hospital, Estonia,
      Tallinn Regionaalhaigla, Estonia and Liverpool Hospital, Sydney, Australia.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>half of the recruited patients will receive intravenous corticosteroid and the other half will receive intravenous isotonic saline as placebo</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The study is double blinded, neither the patients or investigators or nurses managing the drugs do not know whether the patient receives placebo (isotonic saline) or active drug (corticosteroid). In case of emergency the codes can be cracked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>atrial fibrillation</measure>
    <time_frame>three days after mitral valve surgery</time_frame>
    <description>Atrial fibrillation onset in the timeframe of three postoperative days after mitral valve surgery.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Hydrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg 1x3 hydrocortison intravenously for three days after mitral valve surgery or until atrial fibrillation onset</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebos</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100mg 1x3 intravenous fysiologic saline for three days after mitral valve surgery or until atrial fibrillation onset</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>100mg 1x3 hydrocortison intravenously for three days after mitral valve surgery or until atrial fibrillation onset</description>
    <arm_group_label>Hydrocortisone</arm_group_label>
    <other_name>corticosteroid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>100mg 1x3 intravenous fysiologic saline for three days after mitral valve surgery or until atrial fibrillation onset</description>
    <arm_group_label>Placebos</arm_group_label>
    <other_name>placebo, saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  open mitral valve surgery

          -  patients agrees to participate in the study

          -  adult (minimum 18 years of age)

        Exclusion Criteria:

          -  atrial fibrillation onset before first postoperative morning

          -  prolonged intensive care unit stay (patient needs to stay in intensive care unit after
             first postoperative day)

          -  patient is underaged, does not want to participate or can not make the decision by
             himself or herself because of ie memory disability

          -  diabetes mellitus requiring insulin treatment and with recent hypo- or hyperglycemias
             which required hospital treatment

          -  systemic mucous infections

          -  known allergy or oversensitivity to hydrocortisone

          -  Cushing syndrome

          -  history of psychosis

          -  history of ulcus or active ulcus

          -  chronic atrial fibrillation or atrial flutter

          -  corticosteroid or immunosuppressive treatment in use for any reason

          -  active tuberculosis infection

          -  severe renal impairment (serum creatinine 200 umol/l or over)

          -  history of deep or superficial venous trombosis

          -  Herpes simplex -ceratitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jari Halonen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>general surgery attending, clinical teacher</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <zip>70029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 18, 2018</study_first_submitted>
  <study_first_submitted_qc>September 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2018</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>postoperative</keyword>
  <keyword>atrial fibrillation</keyword>
  <keyword>post cardiac surgery</keyword>
  <keyword>corticosteroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD are not to be shared with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

